Novonesis Novo Nordisk Partner to Develop Diabetes Treatments
Okay, here’s a breakdown of the text provided, extracting the key information:
1. Main Subject:
This text is a press release or interaction regarding a partnership between Novonesis and Novo Nordisk focused on microbiome research and its potential impact on metabolic health, notably obesity and type 2 diabetes.They are developing a new platform too discover and develop targeted microbiome solutions.
2. Key Companies & People:
Novonesis: A company involved in biological solutions.
Jens Gamborg: Interim head of External Communication (+45 30 77 71 82, jgam@novonesis.com)
Novo Nordisk: A pharmaceutical company known for diabetes care.
Martin Havtorn Petersen: Global Media & Stakeholder Comms Lead (+45 30 75 52 46, mhpz@novonordisk.com)
3. Core Proclamation:
Novonesis and novo Nordisk are collaborating to create a platform for discovering and developing microbiome-based solutions.
The platform will combine Novonesis’s expertise in microbial strain finding and fermentation with Novo Nordisk’s drug progress capabilities.
The initial focus is on developing solutions for obesity and type 2 diabetes.
The partnership aims to address the growing global health challenges related to metabolic diseases.
4. Supporting Information/References:
Reference 1: A study by Marco ML (2020) defining how microorganisms benefit human health. (https://doi.org/10.1111/1751-7915.13685)
Reference 2: A Science Direct chapter (2019) on the role of prebiotics in disease prevention and health promotion. (https://doi.org/10.1016/B978-0-12-814468-8.00012-0)
Reference 3: World Health Institution data on obesity and overweight (2025). (Link is incomplete in the provided text)
YouTube Link: